Category: Featured

Special Report: Race oncology is further bolstering the expertise of its scientific advisory board with the appointment of an international cardiometabolic expert who has researched the effects of chemotherapy on cardiovascular fitness of cancer patients. Clinical-stage biopharmaceutical company Race Oncology (ASX:RAC) has appointed…

Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Daniel Tillett joins Jonathan Jackson in the Proactive studio to provide an update on the company’s movements over the last few months. Just recently, Race received a $4 million R&D tax incentive tto accelerate clinical development of…

For all the excitement about curing cancer or the disease going into remission, the relief for some patients can often be short-lived if the treatment leaves them with other potentially long-term health repercussions. Cardiovascular health problems are typically the most…

2024 Preview: Race Oncology (ASX:RAC) from Stockhead on Vimeo. Stockhead’s Ashtyn Hiron sits down with Race Oncology (ASX:RAC) CEO Daniel Tillett to close the books on 2023 and gain a sneak peek into what’s around the corner. The clinical stage biopharmaceutical company…

The Race Oncology Annual General Meeting was held on Monday 27 November 2023. During the meeting the Race Board and management team provided an update on the forward-looking strategy, detailed new clinical development plans and explained why we remain extremely…

Clincal stage biopharmaceutical company Race Oncology (ASX:RAC)  says Tillett will work alongside executive director Dr  Pete  Smith,  to advance the company’s  strategic, clinical and commercialisation plans for its core asset reformulated bisantrene, RC220. Read more here.

Race Oncology has announced that Dr Daniel Tillett has been appointed full-time Chief Executive Officer.  Dr Tillett’s appointment is effective immediately and he will work alongside Executive Director, Dr Pete Smith, to advance Race’s strategic, clinical and commercialisation plans for…

Race Oncology (ASX:RAC) has announced positive interim clinical results from an ongoing investigator-initiated Phase II study of its core asset bisantrene in combination with fludarabine and clofarabine in R/R AML patients. Read more here.

Race Oncology Ltd (ASX:RAC) has fielded “impressive” Phase 2 clinical trial results from its Acute Myeloid Leukaemia (AML) clinical trial.   The interim clinical results are from an ongoing investigator-initiated Phase 2 trial of bisantrene in combination with fludarabine and clofarabine in…

Race Oncology Ltd (ASX:RAC) executive director Dr Pete Smith speaks with Proactive soon after announcing the company has initiated the toxicology and safety pharmacology studies required to support human clinical trials of its flagship bisantrene formulation for peripheral infusion, RC220. The company has…